GGrantIndex
Sort

15,842 grants matching pancreatic cancer

Reprogramming PDAC tumor microenvironment to improve immunotherapy

$577,095
Rakesh K. Jain · Massachusetts General Hospital · U01 · FY2021 · CA

Reprogramming PDAC tumor microenvironment to improve immunotherapy

$577,095
Rakesh K. Jain · Massachusetts General Hospital · U01 · FY2020 · CA

Understanding Efficacy and Fe(II)-Promoted Activation of 1,2,4-Trioxolanes in Cancer

$577,035
Eric Collisson · University Of California, San Francisco · R01 · FY2021 · CA

Processed Antigen Characterization by Mass Spectrometry

$577,016
Donald F Hunt · University Of Virginia · R01 · FY2010 · AI

Signal Transduction by Tyrosine Phosphorylation

$577,006
Tony R. Hunter · Salk Institute For Biological Studies · R01 · FY2015 · CA

Biomarker Discovery for Early Detection of Pancreatic Ductal Adenocarcinoma

$576,934
Christopher A Klug · University Of Alabama At Birmingham · P50 · FY2011 · CA

Mechanisms of Murine Turmor Eradication by Immunotherapy

$576,505
Philip D Greenberg · University Of Washington · R01 · FY2016 · CA

Molecular Epidemiology of Pancreatic Cancer

$576,384
Elizabeth A. Holly · University Of California, San Francisco · R01 · FY2006 · CA

Biomarker Discovery for Early Detection of Pancreatic Ductal Adenocarcinoma

$576,372
Christopher A Klug · University Of Alabama At Birmingham · P50 · FY2014 · CA

The Investigation of disease causing genes in C. elegans

$576,181
Andy Golden · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2013 · DK

The MYC Transcription Factor Network and the Path to Cancer

$576,145
Robert Neil Eisenman · Fred Hutchinson Cancer Research Center · R35 · FY2021 · CA

Genomic and genetic studies of endocrine cancers

$576,047
Electron Kebebew · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA

Project 1

$576,031
David J Odde · University Of Minnesota · P01 · FY2021 · CA

Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer

$575,997
Kenneth H. Yu · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA

Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer

$575,993
Kenneth H. Yu · Sloan-Kettering Inst Can Research · R01 · FY2016 · CA

Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer

$575,967
Jeffrey Victor Ravetch · Rockefeller University · R01 · FY2021 · CA

DIRECTLY CONJUGATED SINGLE-DOMAIN VHHS TARGETING MHC CLASS II PRIME T-CELL RESPONSES AGAINST PANCREATIC CANCER NEOANTIGENS

$575,938
Dana-Farber Cancer Institute, Inc. · · FY2016 · Department of Defense

Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer

$575,892
Timothy R Donahue · University Of California Los Angeles · R01 · FY2024 · CA

The Antigen Targeting Core

$575,890
Maria Parkhurst · Division Of Basic Sciences - Nci · ZIC · FY2025 · CA

Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy

$575,716
Farrokh Dehdashti · Washington University · R01 · FY2019 · CA

Designing a Plan of Action for Better Access and Quality of Surgery for African-Americans with Gastrointestinal Cancers in the Deep South

$575,534
Maria Pisu · University Of Alabama At Birmingham · R01 · FY2024 · MD

The Prognostic Significance and Mechanistic Determination of Chromatin Remodeling Biomarkers in Non-Functional Pancreatic Neuroendocrine Tumor

$575,488
Aatur Dilip Singhi · University Of Pittsburgh At Pittsburgh · R37 · FY2023 · CA

Digital Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples

$575,420
Tony Y. Hu · Tulane University Of Louisiana · U01 · FY2024 · CA

The adaptive kinome in pancreatic cancer

$575,301
Jen Jen Yeh · Univ Of North Carolina Chapel Hill · R01 · FY2019 · CA

Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancer

$575,241
Gregory B. Lesinski · Emory University · R01 · FY2024 · CA